Q4 2024 Lisata Therapeutics Inc Earnings Call Transcript

Feb 27, 2025 / 09:30 PM GMT

Release Date Price: $2.4 (+0.42%)

Transcript 10-K8-K

Key Points

Positve

Lisata Therapeutics Inc (LSTA) has advanced its development portfolio, particularly with its novel product candidate, certepatide, for treating advanced solid tumors.
Preliminary results from the Ascend trial's cohort A showed a positive trend in overall survival, including complete responses in the certepatide-treated group.
The company has initiated preclinical investigations of certepatide for treating endometriosis, addressing a significant unmet medical need.
Lisata Therapeutics Inc (LSTA) has secured several special regulatory designations for certepatide, including orphan drug and fast track designations.
The company has a strong financial position with cash equivalents and marketable securities of approximately $31.2 million, supporting operations into the second quarter of 2026.

Negative

The company reported a net loss of $20 million for the year ended December 31, 2024.
There was a decrease in revenue compared to the previous year, with only $1 million generated from an upfront license fee.
The stock experienced a severe reaction following the preliminary data announcement from cohort A of the Ascend trial, indicating potential market misinterpretation.
Lisata Therapeutics Inc (LSTA) has limited control over the release of data from investigator-initiated trials, which may affect timelines and expectations.
The company faces challenges in optimizing dosing schemes for certepatide, as indicated by the need to add cohort B to the Ascend trial.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

LSTA.OQ - Lisata Therapeutics Inc
Q4 2024 Lisata Therapeutics Inc Earnings Call
Feb 27, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to the Lisada Therapeutics Full year 2024 Financial Results and Business update conference call. Currently all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ask a question at that time, please press 11 on your telephone. You will then hear an automated message advising that your hand is raised. As a reminder, this call is being recorded today, Thursday, February 27, 2025. I will now turn the call over to John Mendito, Vice President of Investor Relations and corporate communications at Lisada. Please go ahead, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]
---------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.